To the Editor:
We read with interest the study by Lindholm et al.1
comparing cardioprotection by sevoflurane- and propofol-based anesthesia in patients undergoing elective abdominal aortic surgery. The authors chose cardiac troponin T (cTnT) release determined at one single postoperative time point as the primary endpoint of cardioprotection. No difference between the groups was found, and the authors concluded that “potential cardioprotective effects of volatile anesthetics found in cardiac surgery are less obvious in major vascular surgery.”1
We do not agree with this interpretation of the study results. Neither do we think that this study, as designed a priori and ultimately conducted
, properly addresses the stated hypothesis. First, the cardioprotective effects of sevoflurane are not “less obvious in major vascular surgery
but indeed very similar
to what was reported for volatile anesthetics in previous studies with patients undergoing cardiac surgery in the on-pump2
or off-pump mode.4
In fact, Lindholm et al.1
report a significantly reduced need for inotropic support in the sevoflurane group (P
= 0.003), implying improved cardiac function and reflecting a clear advantage of the sevoflurane-based anesthesia. Unfortunately, this important finding is only briefly mentioned in the Results section and completely ignored in the Discussion. No details on the doses of dopamine and noradrenaline or other potentially administered inotropics such as ephedrine and/or phenylephrine are provided. From the currently available eight randomized trials evaluating volatile anesthetic-induced cardioprotection in patients undergoing off-pump coronary artery bypass graft surgery, a type of surgery which is in many aspects comparable with abdominal aortic aneurysm repair, only three of eight (37%) find reductions in cardiac troponin release, whereas four of eight (50%) find improved cardiac function or reductions in inflammatory markers. Although infarct size and the release of cardiac enzymes are the “definitive standard” of cardioprotection, they are by far not the only clinically relevant outcome measures. Cardioprotection in patient care has already reached a high standard, and any additional protection may be unable to further reduce perioperative release of myocardial necrosis markers, specifically so if the majority of patients are already treated with statins, aspirin, β-blockers, and thoracic epidural anesthetics. In support of this, the use of a volatile anesthetic in cardiac surgical patients potentially reduces long-term cardiovascular complications and mortality, as shown by Garcia et al.
De Hert et al.
despite the clear absence of a reduction in perioperative cardiac troponin release. This notion is compatible with the strong anti-inflammatory and potentially plaque-stabilizing actions of volatile anesthetics5
during the critical perioperative period. We also think that serial postoperative determinations of cTnT should have been obtained in the study by Lindholm et al.1
to reliably map postoperative myocardial damage, and if reporting cTnT values of a single postoperative time point, a histogram of the results displaying ranges of cTnT levels and numbers of patients would provide much more information.
Second, we think that the design of the study by Lindholm et al.1
does not allow to directly answer the hypothesis whether a sevoflurane-based anesthesia as compared with a propofol-based anesthesia is more cardioprotective, because in their sevoflurane group, fentanyl was used as opioid whereas in the propofol group remifentanil was used. Current clinical studies with remifentanil suggest that its cardioprotection may render the protective effects of volatile anesthetics redundant.10–12
Studying the interference in cardioprotection by volatile anesthetics, opioids and propofol in a working rat heart model, we recently demonstrated that remifentanil maintains its protection against ischemia–reperfusion injury in combination with propofol, but does not further enhance protection by sevoflurane.13
Furthermore, in the study by Lindholm et al.
patients randomized to propofol-based anesthesia were clearly more aggressively treated with aspirin and β-blockers, making the study groups unbalanced and shifting cardioprotection in favor of the propofol group. Also, we have recently shown that the volatile anesthetic isoflurane masks cardioprotection by remote ischemic preconditioning in patients undergoing coronary artery bypass surgery.14
Hence, potential cardioprotection by remote ischemic conditioning through aortic cross-clamping, if materializing at all in anesthetized as opposed to awake patients,15
may be less pronounced in the sevoflurane compared with the propofol group.
Finally, it is unfortunate that the cause of death was not available due to restrictions on the access to the registry. In such a case, a prospectively defined cardiovascular evaluation of fatal and nonfatal cardiovascular adverse events including changes in cardiovascular medications during the long-term follow-up is warranted. Unfortunately, the authors also failed to perform logistic regression analyses to identify variables independently associated with cTnT or long-term mortality. Important candidate variables would include group assignment, inotropic support, use of β-blockers, statins, aspirin, and heart rate. Multivariate Cox proportional hazards models should have been used to determine associations of cTnT categories with mortality after serially adjusting for traditional risk factors.
In conclusion, lack of detailed analyses seems to be a major problem of the currently available data evaluating cardioprotection by volatile anesthetics in noncardiac surgery.16
In contrast to the authors themselves, we think that the study by Lindholm et al.1
indeed suggests superior cardioprotection by sevoflurane compared with propofol in patients undergoing noncardiac surgery for abdominal aortic aneurysm repair, despite the multiple limitations and confounding issues as detailed above.
The authors declare no competing interests.
Michael Zaugg, M.D., M.B.A., F.R.C.P.C.
, Eliana Lucchinetti, Ph.D. University of Alberta, Edmonton, Alberta, Canada (M.Z.). firstname.lastname@example.org
1. Lindholm EE, Aune E, Norén CB, Seljeflot I, Hayes T, Otterstad JE, Kirkeboen KA. The anesthesia in abdominal aortic surgery (ABSENT) study: A prospective, randomized, controlled trial comparing troponin T release with fentanyl-sevoflurane and propofol-remifentanil anesthesia in major vascular surgery. ANESTHESIOLOGY. 2013;119:802–12
2. Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, Chassot PG, Schmid ER, Turina MI, von Segesser LK, Pasch T, Spahn DR, Zaugg M. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: A double-blinded, placebo-controlled, multicenter study. ANESTHESIOLOGY. 2003;98:1315–27
3. Lu CC, Ho ST, Wang JJ, Wong CS, Tsai CS, Chang SY, Lin CY. Minimal low-flow isoflurane-based anesthesia benefits patients undergoing coronary revascularization via preventing hyperglycemia and maintaining metabolic homeostasis. Acta Anaesthesiol Sin. 2003;41:165–72
4. Bein B, Renner J, Caliebe D, Scholz J, Paris A, Fraund S, Zaehle W, Tonner PH. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesth Analg. 2005;100:610–6
5. Lucchinetti E, Hofer C, Bestmann L, Hersberger M, Feng J, Zhu M, Furrer L, Schaub MC, Tavakoli R, Genoni M, Zollinger A, Zaugg M. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: Inhalational versus intravenous anesthetics. ANESTHESIOLOGY. 2007;106:444–57
6. Garcia C, Julier K, Bestmann L, Zollinger A, von Segesser LK, Pasch T, Spahn DR, Zaugg M. Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth. 2005;94:159–65
7. De Hert S, Vlasselaers D, Barbé R, Ory JP, Dekegel D, Donnadonni R, Demeere JL, Mulier J, Wouters P. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia. 2009;64:953–60
8. Bignami E, Biondi-Zoccai G, Landoni G, Fochi O, Testa V, Sheiban I, Giunta F, Zangrillo A. Volatile anesthetics reduce mortality in cardiac surgery. J Cardiothorac Vasc Anesth. 2009;23:594–9
9. Jakobsen CJ, Berg H, Hindsholm KB, Faddy N, Sloth E. The influence of propofol versus sevoflurane anesthesia on outcome in 10,535 cardiac surgical procedures. J Cardiothorac Vasc Anesth. 2007;21:664–71
10. Kim TY, Kim DK, Yoon TG, Lim JA, Woo NS, Chee HK, Shin JK, Song MG, Kim SH. Myocardial injury in remifentanil-based anaesthesia for off-pump coronary artery bypass surgery: An equipotent dose of sevoflurane versus propofol. Anaesth Intensive Care. 2011;39:418–25
11. Law-Koune JD, Raynaud C, Liu N, Dubois C, Romano M, Fischler M. Sevoflurane-remifentanil versus propofol-remifentanil anesthesia at a similar bispectral level for off-pump coronary artery surgery: No evidence of reduced myocardial ischemia. J Cardiothorac Vasc Anesth. 2006;20:484–92
12. Wong GT, Huang Z, Ji S, Irwin MG. Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: A randomized trial. J Cardiothorac Vasc Anesth. 2010;24:790–6
13. Zaugg M, Wang L, Zhang L, Lou PH, Lucchinetti E, Clanachan AS. Choice of anesthetic combination determines Ca2+ leak after ischemia-reperfusion injury in the working rat heart: Favorable versus adverse combinations. ANESTHESIOLOGY. 2012;116:648–57
14. Lucchinetti E, Bestmann L, Feng J, Freidank H, Clanachan AS, Finegan BA, Zaugg M. Remote ischemic preconditioning applied during isoflurane inhalation provides no benefit to the myocardium of patients undergoing on-pump coronary artery bypass graft surgery: Lack of synergy or evidence of antagonism in cardioprotection? ANESTHESIOLOGY. 2012;116:296–310
15. Zaugg M, Lucchinetti E, Clanachan A, Finegan B. Remote ischemic preconditioning is redundant in patients undergoing coronary artery bypass graft surgery who are already protected by volatile anesthetics. Circ Res. 2012;110:e42–3; author reply e44–5
16. Zaugg M, Lucchinetti E. Letter by Zaugg and Lucchinetti regarding article, “Randomized comparison of sevoflurane versus propofol to reduce perioperative myocardial ischemia in patients undergoing noncardiac surgery”. Circulation. 2013;127:e875
© 2014 American Society of Anesthesiologists, Inc.